about
Certification in molecular pathology in the United States: an update from the Association for Molecular Pathology Training and Education Committee.A novel TRPC6 mutation in a family with podocytopathy and clinical variability.Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy.Molecular methods of hepatitis C genotyping.Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patientsLaboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: implications for application to clinical testingGenetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it allDevelopment and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsA survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record.VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.Diagnosis of human congenital cytomegalovirus infection by amplification of viral DNA from dried blood spots on perinatal cards.Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients.A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort.Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array.Sensorineural hearing loss in a pediatric population: association of congenital cytomegalovirus infection with intracranial abnormalities.Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001-2009).Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology.Design and analytical validation of clinical DNA sequencing assays.New cytogenetic variant, insertion (15;17)(q22;q12q21), in an adolescent with acute promyelocytic leukemiaFrequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting
P50
Q34296241-16796A0C-AEE5-4B79-938C-A9A655F27955Q34714573-66371EA1-CF2B-4AD3-8A2D-31C54A51D32FQ35233751-0901C8B5-5E64-448F-BFA7-7BA67923C227Q36192689-77DC189C-98A1-459B-B894-13B7A036D1B4Q36598800-29B57491-B516-411D-9C8E-50927CB8B22CQ37024667-43484FBA-8C02-441D-91CA-AA269776BB6CQ37125995-5E5A8BFA-A369-4C5E-9391-940521B6F016Q37138272-97D4C6FE-0B94-42C6-B8F5-A0445F005A5EQ37164469-D551D19A-79F0-488E-8045-1D30144C4D43Q37255253-E118D095-0F80-4A8C-B810-EB93985CE411Q37396256-7344F2BA-2863-413C-8A88-461EBBCB47E7Q37505185-9D8D4881-E82A-4BAB-8D14-E646A3063056Q37633177-F9A0FBAB-C513-4D4A-9813-482B34402920Q39859170-56FD3510-6746-42AE-8A6F-D023C1A4083AQ39918345-3EDC7673-F78E-4354-91BE-2843A08917CFQ42033838-9834B524-0EE6-403F-A311-686DB43D2199Q43967323-D077CF81-06AA-4123-B780-BC8C59057ED7Q44380931-0AB369A6-32C1-47C0-91D1-487EA85DBC85Q46080247-5C64B03C-0BC9-4BE9-8CD3-1A9A0BB184EBQ50436191-2A46E32A-0A16-4A58-85F2-19E1880DC0F5Q50773061-40B20F9C-1C86-469D-9D9E-8141F55A8AB2Q51158107-41A82125-2B8A-4496-8D3E-5CBA66675B19Q52688117-88E442B4-A825-4801-A659-51D0E7DA1E85Q53195100-496B35CD-E7EF-4696-9B0F-715FB13E1A67Q78066999-DFA21DD2-31D8-4A04-853E-0844E6125D19Q91969049-9BEFBDAD-BBF7-4B9B-82D2-E55CF7154F20
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-8516-333X
@en
name
Karen E Weck
@ast
Karen E Weck
@en
Karen E Weck
@es
Karen E Weck
@nl
type
label
Karen E Weck
@ast
Karen E Weck
@en
Karen E Weck
@es
Karen E Weck
@nl
prefLabel
Karen E Weck
@ast
Karen E Weck
@en
Karen E Weck
@es
Karen E Weck
@nl
P106
P21
P31
P496
0000-0002-8516-333X